It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Translation of academic results into clinical practice is a formidable unmet medical need. Single-cell RNA-sequencing (scRNA-seq) studies generate long descriptive ranks of markers with predicted biological function, but without functional validation, it remains challenging to know which markers truly exert the putative function. Given the lengthy/costly nature of validation studies, gene prioritization is required to select candidates. We address these issues by studying tip endothelial cell (EC) marker genes because of their importance for angiogenesis. Here, by tailoring Guidelines On Target Assessment for Innovative Therapeutics, we in silico prioritize previously unreported/poorly described, high-ranking tip EC markers. Notably, functional validation reveals that four of six candidates behave as tip EC genes. We even discover a tip EC function for a gene lacking in-depth functional annotation. Thus, validating prioritized genes from scRNA-seq studies offers opportunities for identifying targets to be considered for possible translation, but not all top-ranked scRNA-seq markers exert the predicted function.
Harnessing existing scRNA-seq data, a set of new tip endothelial cell markers is described to demonstrate the need for targeted assessment and prioritization of candidate genes.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 Leuven Cancer Institute (LKI), Laboratory of Angiogenesis and Vascular Metabolism, Center for Cancer Biology (CCB), VIB and Department of Oncology, KU Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884)
2 Leuven Cancer Institute (LKI), Laboratory of Angiogenesis and Vascular Metabolism, Center for Cancer Biology (CCB), VIB and Department of Oncology, KU Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884); BIOCEV, Institute of Biotechnology of the Czech Academy of Sciences, Vestec, Czech Republic (GRID:grid.448014.d)
3 Leuven Cancer Institute (LKI), Laboratory of Angiogenesis and Vascular Metabolism, Center for Cancer Biology (CCB), VIB and Department of Oncology, KU Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884); Aarhus University, Laboratory of Angiogenesis and Vascular Heterogeneity, Department of Biomedicine, Aarhus C, Denmark (GRID:grid.7048.b) (ISNI:0000 0001 1956 2722)
4 Leuven Cancer Institute (LKI), Laboratory of Angiogenesis and Vascular Metabolism, Center for Cancer Biology (CCB), VIB and Department of Oncology, KU Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884); CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria (GRID:grid.418729.1) (ISNI:0000 0004 0392 6802)
5 Leuven Cancer Institute (LKI), Laboratory of Angiogenesis and Vascular Metabolism, Center for Cancer Biology (CCB), VIB and Department of Oncology, KU Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884); Aarhus University, Laboratory of Angiogenesis and Vascular Heterogeneity, Department of Biomedicine, Aarhus C, Denmark (GRID:grid.7048.b) (ISNI:0000 0001 1956 2722); Khalifa University of Science and Technology, Center for Biotechnology, Abu Dhabi, United Arab Emirates (GRID:grid.440568.b) (ISNI:0000 0004 1762 9729)